If your potential market is “all aging people”, that’s a pretty big market. Even better when you realize that as people are older, they have more money, so the market you’re targeting tends to have more money to spend on medical expenses.
Now, couple that with a highly competitive landscape where the first to market will capture the vast majority of that market and you can see how some steps might get skipped.
Finally, if we did have random results in clinical trials, if you had 20 companies running a trial, you could expect at one of them to randomly have a positive trial (p <= 0.05). So you could have “promising” results for a small trial that would only fail once you had a larger number of participants.
The market incentives and potential for lost opportunities were probably enough to justify a larger risk for some companies.
> Did the 56 Work Lead to Clinical Trials?
> [snip] And the answer is that no, I have been unable to find a clinical trial that specifically targeted the AB56 oligomer itself
It was industry (well short traders) that led to this being uncovered:
> He was originally hired by two other neuroscientists who also sell biopharma stocks short - my kind of people, to be honest - to investigate published research related to Cassava Sciences and their drug Simufilam, and that work led him deeper into the amyloid literature.
Due dill is hard. Why did no one catch ubeam? Why is energous still a thing? Why has no one called out LAZR on their nonsense?
Because they made even more off it.
No, Alzheimer's has been a multibillion dollar sinkhole for drug development cash with absolutely nothing to show for it.